Pharsight

1. List of Airduo Digihaler drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173259 (Pediatric)	TEVA PHARM	Drug delivery device with electronics and power management	Jan, 2041 (17 years from now)
US11266796	TEVA PHARM	Inhalation device with integrated electronics	Feb, 2041 (18 years from now)
US11266796 (Pediatric)	TEVA PHARM	Inhalation device with integrated electronics	Aug, 2041 (18 years from now)

Exclusivity	Exclusivity Expiration
M	Jul 9, 2024
Pediatric Exclusivity (PED)	Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.113MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.232MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription

2. List of Armonair Digihaler drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173259 (Pediatric)	TEVA PHARM	Drug delivery device with electronics and power management	Jan, 2041 (17 years from now)
US11266796	TEVA PHARM	Inhalation device with integrated electronics	Feb, 2041 (18 years from now)
US11266796 (Pediatric)	TEVA PHARM	Inhalation device with integrated electronics	Aug, 2041 (18 years from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Jul 9, 2024
New Strength (NS)	Jul 9, 2024
Pediatric Exclusivity (PED)	Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.03MG/INH	POWDER;INHALATION	Discontinued
0.055MG/INH	POWDER;INHALATION	Discontinued
0.113MG/INH	POWDER;INHALATION	Discontinued
0.232MG/INH	POWDER;INHALATION	Discontinued

3. List of Dapzura Rt drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173189	BAXTER HLTHCARE CORP	Daptomycin formulations containing a combination of sorbitol and mannitol	Mar, 2041 (18 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 25 January, 2022

Treatment: Method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
500MG/VIAL	POWDER;INTRAVENOUS	Prescription

4. List of Epidiolex drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11406623	GW RES LTD	Methods of treating tuberous sclerosis complex with cannabidiol and everolimus	Mar, 2041 (18 years from now)
US11160795	GW RES LTD	Methods of treating tuberous sclerosis complex with cannabidiol and everolimus	Mar, 2041 (18 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 28, 2023
Orphan Drug Exclusivity (ODE)	Jul 31, 2027
New Patient Population (NPP)	Jul 31, 2023

Drugs and Companies using CANNABIDIOL ingredient

NCE-1 date: September, 2022

Market Authorisation Date: 28 September, 2018

Treatment: Use for the treatment of seizures associated with tuberous sclerosis complex in patients taking everolimus

Dosage: SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg/mL	28 Sep, 2022	10		01 Mar, 2041

Strength	Dosage	Availability
100MG/ML	SOLUTION;ORAL	Prescription

5. List of Exparel drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11426348	PACIRA PHARMS INC	Compositions of bupivacaine multivesicular liposomes	Jan, 2041 (17 years from now)
US11452691	PACIRA PHARMS INC	Compositions of bupivacaine multivesicular liposomes	Jan, 2041 (17 years from now)
US11357727	PACIRA PHARMS INC	Manufacturing of bupivacaine multivesicular liposomes	Jan, 2041 (17 years from now)
US11311486	PACIRA PHARMS INC	Manufacturing of bupivacaine multivesicular liposomes	Jan, 2041 (17 years from now)
US11304904	PACIRA PHARMS INC	Manufacturing of bupivacaine multivesicular liposomes	Jan, 2041 (17 years from now)
US11033495	PACIRA PHARMS INC	Manufacturing of bupivacaine multivesicular liposomes	Jan, 2041 (17 years from now)
US11179336	PACIRA PHARMS INC	Manufacturing of bupivacaine multivesicular liposomes	Jan, 2041 (17 years from now)
US11278494	PACIRA PHARMS INC	Manufacturing of bupivacaine multivesicular liposomes	Jan, 2041 (17 years from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Mar 22, 2024

Drugs and Companies using BUPIVACAINE ingredient

Market Authorisation Date: 28 October, 2011

Treatment: Method of treating pain, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia; Method of treating pain, for example, via infiltration for local analgesia or via nerve block, for example, nterscalene brachial plexus for regional analgesia; Method of treating pain, for example, treating postsurgical pain via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia; Method of providing local or regional analgesia via infiltration for local analgesia or via interscalene brachial plexus nerve block or femoral nerve block for regional analgesia; Method of providing postsurgical pain management, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia

Dosage: INJECTABLE, LIPOSOMAL;INJECTION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
133 mg/10 mL	28 Dec, 2021	1		22 Jan, 2024
266 mg/20 mL	20 Aug, 2021	1		22 Jan, 2041

Strength	Dosage	Availability
133MG/10ML (13.3MG/ML)	INJECTABLE, LIPOSOMAL;INJECTION	Prescription
266MG/20ML (13.3MG/ML)	INJECTABLE, LIPOSOMAL;INJECTION	Prescription

6. List of Invega Hafyera drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11304951	JANSSEN PHARMS	Dosing regimens associated with extended release paliperidone injectable formulations	May, 2041 (18 years from now)
US11324751	JANSSEN PHARMS	Dosing regimens associated with extended release paliperidone injectable formulations	May, 2041 (18 years from now)

Exclusivity	Exclusivity Expiration
New Strength (NS)	Aug 30, 2024

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Market Authorisation Date: 18 May, 2015

Treatment: Reinitiation of schizophrenia treatment wherein more than 6 months 3 weeks but less than 8 months have elapsed since the last dose; Treatment of schizophrenia by administering a dose up to two weeks before or three weeks after the scheduled six-month dose

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Submission Date	ANDA(s) Filed	Last patent expiry
546 mg/1.75 mL	24 Jun, 2020	1	05 Apr, 2036
819 mg/2.625 mL	30 Apr, 2021	1	05 Apr, 2036
273 mg/0.875 mL and 410 mg/1.315 mL	14 Jul, 2021	1	05 Apr, 2036

Strength	Dosage	Availability
1.092GM/3.5ML (312MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
1.560GM/5ML (312MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
273MG/0.875ML (273MG/0.875ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
410MG/1.315ML (311.79MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
546MG/1.75ML (312MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
819MG/2.625ML (312MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

7. List of Lyvispah drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11491125	AMNEAL	Baclofen formulations and methods of minimizing patient exposure to metabolite variations	Sep, 2041 (18 years from now)

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 22 November, 2021

Treatment: Treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity; Treatment of spasticity resulting from spinal cord injuries and other spinal cord diseases

Dosage: GRANULES;ORAL

Strength	Dosage	Availability
5MG/PACKET	GRANULES;ORAL	Prescription
10MG/PACKET	GRANULES;ORAL	Prescription
20MG/PACKET	GRANULES;ORAL	Prescription

8. List of Norliqva drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458095	CMP DEV LLC	NA	Feb, 2041 (18 years from now)
US11253474	CMP DEV LLC	Pharmaceutical solution of amlodipine	Feb, 2041 (18 years from now)

Drugs and Companies using AMLODIPINE BESYLATE ingredient

Market Authorisation Date: 24 February, 2022

Treatment: Norliqva is indicated for the treatment of hypertension, to lower blood pressure in adults and children 6 years of age and older; Norliqva is indicated for the symptomatic treatment of chronic stable angina; Norliqva is indicated for the treatment of confirmed or suspected vasospastic angina

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
EQ 1MG BASE/ML	SOLUTION;ORAL	Prescription

9. List of Posimir drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11400019	INNOCOLL	Sustained release drug delivery systems with reduced impurities and related methods	Jan, 2041 (17 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Feb 1, 2024

Drugs and Companies using BUPIVACAINE ingredient

Market Authorisation Date: 01 February, 2021

Treatment: NA

Dosage: SOLUTION, EXTENDED RELEASE;INFILTRATION

Strength	Dosage	Availability
660MG/5ML (132MG/ML)	SOLUTION, EXTENDED RELEASE;INFILTRATION	Prescription

10. List of Proair Digihaler drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11266796	TEVA BRANDED PHARM	Inhalation device with integrated electronics	Feb, 2041 (18 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

Strength	Dosage	Availability
EQ 0.09MG BASE/INH	POWDER, METERED;INHALATION	Prescription

11. List of Tlando drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11464735	ANTARES PHARMA INC	Fixed dose oral testosterone undecanoate compositions and use thereof	Apr, 2041 (18 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Mar 28, 2025

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 28 March, 2022

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypogonadism (congenital or acquired).

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
112.5MG	CAPSULE;ORAL	Prescription

12. List of Veklury drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11491169	GILEAD SCIENCES INC	Remdesivir treatment methods	May, 2041 (18 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Oct 22, 2025
New Patient Population (NPP)	Apr 25, 2025
New Dosing Schedule (D)	Jan 21, 2025

Drugs and Companies using REMDESIVIR ingredient

NCE-1 date: October, 2024

Market Authorisation Date: 22 October, 2020

Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 28 days of age and 3 kg) requiring hospitalization and for whom concomitant use of chloroquine, or an analog or sale thereof, is not recommended; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 28 days of age and 3 kg) and for whom concomitant use of chloroquine, or an analog or salt thereof, is not recommended

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
100MG/VIAL	POWDER;INTRAVENOUS	Prescription
100MG/20ML (5MG/ML)	SOLUTION;INTRAVENOUS	Prescription

13. List of Wegovy drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11318191	NOVO	GLP-1 compositions and uses thereof	Feb, 2041 (18 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 5, 2022
New Product (NP)	Jun 4, 2024

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 04 June, 2021

Treatment: Method for weight management

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
0.25MG/0.5ML (0.25MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
0.5MG/0.5ML (0.5MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
1MG/0.5ML (1MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
1.7MG/0.75ML (1.7MG/0.75ML)	SOLUTION;SUBCUTANEOUS	Prescription
2.4MG/0.75ML (2.4MG/0.75ML)	SOLUTION;SUBCUTANEOUS	Prescription